New hope for kidney patients battling depression: study tests two novel therapies

NCT ID NCT04422652

Ongoing Disease control Sponsor: Stony Brook University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study aims to find better ways to treat depression in people with chronic kidney disease (CKD). About 201 adults with advanced CKD and major depression will receive either behavioral activation teletherapy plus a non-SSRI antidepressant, or the antidepressant plus teletherapy, or a placebo with clinical management. The goal is to see which approach improves mood, quality of life, and treatment adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES END STAGE KIDNEY DISEASE (ESRD) MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Parkland Health and Hospital System

Dallas, Texas, 75235, United States
Stony Brook University Medical Center

Stony Brook, New York, 11794-8430, United States
UT Southwestern and Affiliates

Dallas, Texas, 75390, United States
University of Washington

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.